Teva’s Allergan acquisition approved by FTC

28-07-2016

Teva’s Allergan acquisition approved by FTC

Photo: Courtesy of Teva

Teva announced yesterday that the Federal Trade Commission (FTC) has accepted its proposed $40.5 billion buyout of Allergan’s generics business after the Isreal-based company agreed to sell nearly 80 products to address competition concerns.


Teva, Allergan, FTC, anticompetitive, generics, acquisition

LSIPR